Evotec SE
XETRA:EVT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Evotec SE
Accounts Payable
Evotec SE
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
E
|
Evotec SE
XETRA:EVT
|
Accounts Payable
€99.1m
|
CAGR 3-Years
22%
|
CAGR 5-Years
25%
|
CAGR 10-Years
32%
|
Gerresheimer AG
XETRA:GXI
|
Accounts Payable
€322.4m
|
CAGR 3-Years
27%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
S
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Accounts Payable
€90.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Evotec SE's Accounts Payable?
Accounts Payable
99.1m
EUR
Based on the financial report for Mar 31, 2024, Evotec SE's Accounts Payable amounts to 99.1m EUR.
What is Evotec SE's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
32%
Over the last year, the Accounts Payable growth was 2%. The average annual Accounts Payable growth rates for Evotec SE have been 22% over the past three years , 25% over the past five years , and 32% over the past ten years .